Little is known about the association between lipoprotein(a) [Lp(a)] levels and future ischemic cardiovascular events in patients with premature acute coronary syndrome (ACS). A total of 1464 consecutive patients who underwent coronary angiography for premature ACS (males <45 years and females <55 years) were enrolled in this study. Patients were divided into quartiles according to serum Lp(a) levels (Q1: ≤11.1 nmol/L; Q2: 11.1-27.7 nmol/L; Q3: 27.7-79.3 nmol/L; and Q4: >79.3 nmol/L). Major adverse cardiovascular events (MACEs) increased with Lp(a) quartiles after 2-year follow-up (among quartiles, respectively; P = .001). Kaplan-Meier curves revealed significant differences in event-free survival rates among Lp(a) quartile groups (P = .001). Multivariate Cox proportional hazards regression analysis indicated that serum Lp(a) level was an independent predictor of MACE either as a continuous variable (hazard ratio [HR]: 1.002, 95% confidence interval [CI]: 1.001-1.004; P = .009) or as a categorical variable (HR: 1.443, 95% CI: 1.074-1.937; P = .015). Furthermore, Lp(a) levels (as a variable) significantly improved the prognostic value for MACE. These findings suggest that Lp(a) measurement has value for cardiovascular risk stratification in patients with premature ACS.
ZhangTTianRZhangSWuW. Clinical features of patients with premature acute coronary syndrome. Zhonghua Xin Xue Guan Bing Za Zhi. 2014;42(5):392–5.
2.
VedanthanRSeligmanBFusterV. Global perspective on acute coronary syndrome. Circ Res. 2014;114(12):1959–75.
3.
SedlakTLIzadnegahdarM. Outcomes in premature acute coronary syndrome: has the sex gap closed?Can J Cardiol. 2016;32(12):1375–77.
4.
WangXGaoMZhouS, et al.Trend in young coronary artery disease in china from 2010 to 2014: a retrospective study of young patients ≤ 45. BMC Cardiovasc Disord. 2017;17(1):18.
5.
JacobsonTA. Lipoprotein(a), cardiovascular disease, and contemporary management. Mayo Clin Proc. 2013;88(11):1294–311.
6.
KassnerUSchlabsTRosadaASteinhagen-ThiessenE. Lipoprotein(a)—an independent causal risk factor for cardiovascular disease and current therapeutic options. Atheroscler Suppl. 2015;18:263–7.
7.
ForbesCAQuekRGWDeshpandeS, et al.The relationship between Lp(a) and CVD outcomes: a systematic review. Lipids Health Dis. 2016;15(1):95.
8.
DaiWLongJChengYChenYZhaoS. Elevated plasma lipoprotein(a) levels were associated with increased risk of cardiovascular events in chinese patients with stable coronary artery disease. Sci Rep. 2018;8(1):7726.
9.
NestelPJBarnesEHTonkinAM, et al.Plasma lipoprotein(a) concentration predicts future coronary and cardiovascular events in patients with stable coronary heart disease. Arterioscler Thromb Vasc Biol. 2013;33(12):2902–8.
10.
Sanchez Muñoz-TorreroJFRico-MartínSÁlvarezLRAguilarEAlcaláJNMonrealM. Lipoprotein(a) levels and outcomes in stable outpatients with symptomatic artery disease. Atherosclerosis. 2018;276:10–4.
11.
O’DonoghueMLMorrowDATsimikasS, et al.Lipoprotein(a) for risk assessment in patients with established coronary artery disease. J Am Coll Cardiol. 2014;63(6):520–7.
12.
KwonSWKimJ-YSungJM, et al.Elevated lipoprotein(a) has incremental prognostic value in type 2 diabetic patients with symptomatic coronary artery disease. J Atheroscler Thromb. 2015;22(5):527–34.
13.
KonishiHMiyauchiKShitaraJ, et al.Impact of lipoprotein(a) on long-term outcomes in patients with diabetes mellitus who underwent percutaneous coronary intervention. Am J Cardiol. 2016;118(12):1781–5.
14.
KonishiHMiyauchiKKasaiT, et al.Impact of lipoprotein(a) as residual risk on long-term outcomes in patients after percutaneous coronary intervention. Am J Cardiol. 2015;115(2):157–60.
15.
SuwaSOgitaMMiyauchiK, et al.Impact of lipoprotein(a) on long-term outcomes in patients with coronary artery disease treated with statin after a first percutaneous coronary intervention. J Atheroscler Thromb. 2017;24(11):1125–31.
16.
XuNXfTYaoY, et al.Association of plasma lipoprotein(a) with long-term adverse events in patients with chronic kidney disease who underwent percutaneous coronary intervention. Am J Cardiol. 2018;122(12):2043–8.
17.
KonishiHMiyauchiKTsuboiS, et al.Plasma lipoprotein(a) predicts major cardiovascular events in patients with chronic kidney disease who undergo percutaneous coronary intervention. Int J Cardiol. 2016;205:50–3.
18.
FengZLiHlWjB, et al.Association of lipoprotein(a) with long-term mortality following coronary angiography or percutaneous coronary intervention. Clin Cardiol. 2017;40(9):674–8.
19.
ParkSHRhaSWChoiBG, et al.Impact of high lipoprotein(a) levels on in-stent restenosis and long-term clinical outcomes of angina pectoris patients undergoing percutaneous coronary intervention with drug-eluting stents in asian population. Clin Exp Pharmacol Physiol. 2015;42(6):588–95.
20.
GenestJJMartin-MunleySSMcNamaraJR, et al.Familial lipoprotein disorders in patients with premature coronary artery disease. Circulation. 1992;85(6):2025–33.
21.
RallidisLSPavlakisGFoscolouA, et al.High levels of lipoprotein(a) and premature acute coronary syndrome. Atherosclerosis. 2018;269:29–34.
22.
AndersonJLAdamsCDAntmanEM, et al.2012 ACCF/AHA focused update incorporated into the ACCF/AHA 2007 guidelines for the management of patients with unstable angina/non–ST-elevation myocardial infarction. J Am Coll Cardiol. 2013;61(23):e179–347.
23.
KushnerFGHandMSmithSC, et al.2009 focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update): A report of the american college of cardiology foundation/american heart association task force on practice guidelines. J Am Coll Cardiol. 2009;54(23):2205–41.
24.
GuevaraJKnappRDHondaSNorthupSRMorrisettJD. A structural assessment of the apo[a] protein of human lipoprotein[a]. Proteins: Struct, Funct, Genet. 1992;12(2):188–99.
25.
ChoJYJeongMHAhnY, et al.High lipoprotein(a) levels are associated with long-term adverse outcomes in acute myocardial infarction patients in high killip classes. Korean Circ J. 2010;40(10):491–8.
26.
IkenagaHIshiharaMInoueI, et al.Usefulness of lipoprotein(a) for predicting progression of non-culprit coronary lesions after acute myocardial infarction. Circ J. 2011;75(12):2847–52.
27.
MitsudaTUemuraYIshiiH, et al.Lipoprotein(a) levels predict adverse vascular events after acute myocardial infarction. Heart Vessels. 2016;31(12):1923–9.
28.
ZhouJCuiXJinX, et al.Association between lipoprotein(a) level on admission and the incidence of subsequent cardiovascular events in patients with acute coronary syndrome. Int J Cardiol. 2012;158(3):464–6.
29.
SchwartzGGBallantyneCMBarterPJ, et al.Association of lipoprotein(a) with risk of recurrent ischemic events following acute coronary syndrome. JAMA Cardiology. 2018;3(2):164–8.
30.
ZewingerSKleberMTraganteV, et al.Relations between lipoprotein(a) concentrations, LPA genetic variants, and the risk of mortality in patients with established coronary heart disease: a molecular and genetic association study. Lancet Diabetes Endocrinol. 2017;5(7):534–43.
31.
WeissMCBergerJSGianosE, et al.Lipoprotein(a) screening in patients with controlled traditional risk factors undergoing percutaneous coronary intervention. J Clin Lipidol. 2017;11(5):1177–80.
32.
AfsharMPiloteLDufresneLEngertJCThanassoulisG. Lipoprotein(a) interactions with low-density lipoprotein cholesterol and other cardiovascular risk factors in premature acute coronary syndrome (ACS). J Am Heart Assoc. 2016;5(4):1–8.
33.
EnasEAChackoVSenthilkumarAPuthumanaNMohanV. Elevated lipoprotein(a)—a genetic risk factor for premature vascular disease in people with and without standard risk factors: a review. Dis Mon. 2006;52(1):5–50.
34.
WilleitPKiechlSKronenbergF, et al.Discrimination and net reclassification of cardiovascular risk with lipoprotein(a). J Am Coll Cardiol. 2014;64(9):851–60.
35.
KamstrupPRTybjærg-HansenANordestgaardBG. Extreme lipoprotein(a) levels and improved cardiovascular risk prediction. J Am Coll Cardiol. 2013;61(11):1146–56.
36.
VandermolenSAbbottJDe SilvaK. What’s age got to do with it? A review of contemporary revascularization in the elderly. Curr Cardiol Rev.2015;11(3):199–208.
37.
TangXFSongYXuJJ, et al.Effect of sex difference in clinical presentation (stable coronary artery disease vs unstable angina pectoris or non-ST-elevation myocardial infarction vs ST-elevation myocardial infarction) on 2-year outcomes in patients undergoing percutaneous coronary intervention. J Interv Cardiol. 2018; 31(1):1–10.
38.
WadheraRKSteenDLKhanIGiuglianoRPFoodyJM. A review of low-density lipoprotein cholesterol, treatment strategies, and its impact on cardiovascular disease morbidity and mortality. J Clin Lipidol. 2016,10(3):472–89.
39.
ChiengDPangJEllisKLHillisGSWattsGFSchultzCJ. Elevated lipoprotein(a) and low-density lipoprotein cholesterol as predictors of the severity and complexity of angiographic lesions in patients with premature coronary artery disease. J Clin Lipidol. 2018;12(4):1019–26.
40.
NiccoliGCinDScaloneG, et al.Lipoprotein(a) is related to coronary atherosclerotic burden and a vulnerable plaque phenotype in angiographically obstructive coronary artery disease. Atherosclerosis. 2016;246:214–20.
41.
HikitaHShigetaTKojimaK, et al.Lipoprotein(a) is an important factor to determine coronary artery plaque morphology in patients with acute myocardial infarction. Coron Artery Dis. 2013;24(5):381–5.
42.
VerweijSLde RondeMWJVerbeekR, et al.Elevated lipoprotein(a) levels are associated with coronary artery calcium scores in asymptomatic individuals with a family history of premature atherosclerotic cardiovascular disease. J Clin Lipidol. 2018;12(3):597–603.
43.
FanYHuJSGuoFLuZBXiaH. Lipoprotein(a) as a predictor of poor collateral circulation in patients with chronic stable coronary heart disease. Braz J Med Biol Res. 2017;50(8):e5979.
44.
NozueTYamamotoSTohyamaS, et al.Lipoprotein(a) is associated with necrotic core progression of non-culprit coronary lesions in statin-treated patients with angina pectoris. Lipids Health Dis. 2014;13(1):59.
45.
NordestgaardBGChapmanMJRayK, et al.Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J. 2010;31(23):2844–53.
46.
AdhyaruBBJacobsonTA. New cholesterol guidelines for the management of atherosclerotic cardiovascular disease risk. Endocrinol Metab Clin North Am. 2016;45(1):17–37.
47.
ParéGÇakuAMcQueenM, et al.Lipoprotein(a) levels and the risk of myocardial infarction among 7 ethnic groups. Circulation. 2019;139(12):1472–82.
